Enliven Therapeutics Inc. (ELVN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Enliven Therapeutics Inc.

    NASDAQ: ELVN · Real-Time Price · USD
    20.01
    1.44 (7.75%)
    At close: Sep 26, 2025, 3:59 PM
    20.10
    0.45%
    After-hours: Sep 26, 2025, 06:56 PM EDT

    Enliven Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 317K 297K 622K 99K
    Gross Profit
    		 -317K -297K -622K -99K
    Operating Income
    		 -104.55M -83.53M -38.79M -24.76M
    Interest Income
    		 14.89M 11.97M 1.13M 22K
    Pretax Income
    		 -88.79M -71.58M 1.58M -24.74M
    Net Income
    		 -89.02M -71.58M -37.66M -24.72M
    Selling & General & Admin
    		 23.78M 18.95M 7.77M 4.29M
    Research & Development
    		 80.46M 64.57M 31.02M 20.47M
    Other Expenses
    		 317K n/a -5.14M n/a
    Operating Expenses
    		 104.55M 83.53M 33.65M 24.76M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 104.55M 83.53M 34.27M 24.76M
    Income Tax Expense
    		 -232K n/a 88K -22K
    Shares Outstanding (Basic)
    		 47.07M 35.55M 6.25M 7.81M
    Shares Outstanding (Diluted)
    		 47.07M 35.55M 6.25M 7.82M
    EPS (Basic)
    		 -1.89 -2.01 -6.03 -3.17
    EPS (Diluted)
    		 -1.89 -2.01 -6.03 -3.17
    EBITDA
    		 -88.47M -81.93M -38.58M -24.65M
    EBIT
    		 -88.79M -82.23M -38.79M -24.76M
    Depreciation & Amortization
    		 317K 297K 215K 115K

    Add to Watchlist